Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Lumryz™ (sodium oxybate) – New orphan drug approval
May 1, 2023 - Avadel announced the FDA approval of Lumryz (sodium oxybate), for the treatment of cataplexy or excessive daytime sleepiness in adults with narcolepsy.
